54,307 Shares in Arcutis Biotherapeutics, Inc. $ARQT Purchased by RFG Advisory LLC

RFG Advisory LLC bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 54,307 shares of the company’s stock, valued at approximately $1,577,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Zevenbergen Capital Investments LLC purchased a new position in Arcutis Biotherapeutics during the fourth quarter valued at approximately $12,140,000. Nordea Investment Management AB purchased a new position in Arcutis Biotherapeutics during the fourth quarter valued at approximately $5,850,000. UBS Group AG raised its position in Arcutis Biotherapeutics by 10.0% during the fourth quarter. UBS Group AG now owns 3,243,432 shares of the company’s stock valued at $94,189,000 after acquiring an additional 294,994 shares in the last quarter. Ally Bridge Group NY LLC purchased a new position in Arcutis Biotherapeutics during the third quarter valued at approximately $4,396,000. Finally, Jennison Associates LLC raised its position in Arcutis Biotherapeutics by 10.3% during the third quarter. Jennison Associates LLC now owns 12,254,119 shares of the company’s stock valued at $230,990,000 after acquiring an additional 1,144,714 shares in the last quarter.

Arcutis Biotherapeutics Stock Up 2.5%

Shares of ARQT opened at $21.17 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.99 and a debt-to-equity ratio of 0.54. Arcutis Biotherapeutics, Inc. has a 12 month low of $12.72 and a 12 month high of $31.77. The stock’s 50 day moving average is $23.65 and its two-hundred day moving average is $25.77. The firm has a market cap of $2.65 billion, a P/E ratio of -705.43 and a beta of 1.58.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). Arcutis Biotherapeutics had a negative net margin of 0.57% and a negative return on equity of 1.41%. The business had revenue of $105.40 million during the quarter, compared to analyst estimates of $103.68 million. Analysts predict that Arcutis Biotherapeutics, Inc. will post 0.18 earnings per share for the current fiscal year.

Key Headlines Impacting Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $34 price target on Arcutis Biotherapeutics while raising near-term EPS estimates for 2026 quarters, reinforcing the view that earnings could improve as ZORYVE sales scale. Article Title
• Positive Sentiment: Needham also reiterated its Buy rating with a $36 target, helping sentiment by signaling that analysts still see meaningful upside from current levels.
• Positive Sentiment: The company reported a $105.4 million quarterly revenue beat and highlighted strong ZORYVE momentum, including commercial growth and pipeline progress, which remains a key driver for investor enthusiasm. Article Title
• Neutral Sentiment: Arcutis announced inducement grants to 40 new hires, a routine equity compensation move that signals continued hiring but is not likely to materially change the stock’s near-term outlook. Article Title
• Neutral Sentiment: HC Wainwright’s mix of higher and lower out-year estimates suggests analysts remain constructive overall, but are still fine-tuning the longer-term earnings model. Article Title
• Negative Sentiment: Q1 EPS missed expectations, showing Arcutis is still spending heavily as it grows; that profitability gap could limit upside if investors focus on margins rather than sales growth. Article Title
• Negative Sentiment: Several insiders sold shares under pre-arranged 10b5-1 plans, which is routine, but clustered selling can still weigh on sentiment in the short term. Article Title

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Mizuho reduced their price target on Arcutis Biotherapeutics from $37.00 to $35.00 and set an “outperform” rating for the company in a research report on Monday, March 2nd. TD Cowen lifted their price target on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcutis Biotherapeutics in a research report on Friday, March 27th. HC Wainwright lifted their price target on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $36.00 price target on shares of Arcutis Biotherapeutics in a research report on Thursday. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Insider Buying and Selling

In other Arcutis Biotherapeutics news, insider Masaru Matsuda sold 8,256 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $23.31, for a total value of $192,447.36. Following the sale, the insider directly owned 126,689 shares of the company’s stock, valued at approximately $2,953,120.59. This trade represents a 6.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Watanabe sold 3,172 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $23.61, for a total value of $74,890.92. Following the completion of the sale, the insider directly owned 720,755 shares in the company, valued at approximately $17,017,025.55. The trade was a 0.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 92,831 shares of company stock valued at $2,295,499 in the last 90 days. Corporate insiders own 9.40% of the company’s stock.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.